Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.11 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: luspatercept, bintrafusp alfa, fresolimumab +2 | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 11 Parkinson's papers of 3,266 | 0.67 |
| pathways Reactome | 21 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2451
Sealed predictions
- TGFB1 in dopamine neurons, braak-0.37 (p 0.324) → -0.09 (p 0.815)receipt 2460
Swarm cases
receipt 2460: TGFB1 in dopamine neurons, braak
- power
- full sample -0.23 (p 0.360, n 18), 95% CI -0.63 to +0.27. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.26 (p 0.289, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.31 (p 0.207, n 18). could be the mix.
- skeptic
- leave-one-out range -0.41 to -0.15, sign flips 0; without severely affected donors -0.23 (p 0.360, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TGFB1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts